Global Hepatitis C Testing Market Size By Test Kits (Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test), By Technique (Immunoassays, Polymerase Chain Reaction), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast
C형 간염 검사 시장 규모와 예측
C형 간염 검사 시장 규모는 2024년에 14억 8,000만 달러로 평가되었고 2026-2032년에 걸쳐 CAGR 7.50%를 나타내, 2032년에는 25억 1,000만 달러에 달할 것으로 예측됩니다.
- C형 간염 검사는 C형 간염 바이러스(HCV) 감염을 관리하기 위한 중요한 요소입니다.
- HCV 감염은 항바이러스제에 의해 고도로 치료 가능합니다.효과적인 치료는 치유에 연결되어, 간질환의 진행을 막을 수 있습니다.
- 간경변이나 간암 등의 합병증을 막기 위해서는 조기 진단과 치료가 필수적입니다.
- 미국 질병 예방 관리 센터(CDC)에 의하면, C형 간염 환자의 3명에 1명 가까이 자신의 감염 상태를 인지하고 있지 않습니다.
- CDC는 18세 이상의 모든 성인과 임신 중의 모든 사람에게, 임신 기간중의 보편적인 C형 간염 스크리닝을 추천하고 있습니다.
- CDC는 특정 고위험 그룹의 사람들을 더 자주 검사하는 것이 좋습니다.
세계의 C형 간염 검사 시장 역학
세계의 C형 간염 검사 시장을 형성하는 주요 시장 역학은 다음과 같습니다.
주요 시장 성장 촉진요인
- C형 간염의 유병률 상승 : C형 간염 바이러스(HCV) 감염의 유병률 증가가 검사 수요를 촉진하고 있습니다.
- 계발과 스크리닝 프로그램의 확대 계발 캠페인과 스크리닝 프로그램의 확대가 C형 간염 검사 시장의 성장을 가속하고 있습니다.
- 포인트 오브 케어 검사의 동향 : 신속한 포인트 오브 케어 검사로의 변화는 C형 간염 검사의 상황을 지배하고 있습니다.
- 진단기술의 진보 : 기술의 진보가 C형 간염검사법의 혁신을 뒷받침하고 있습니다.
주요 이슈
- 제한된 인식과 스티그마가 검사율을 저해하고 있습니다.
- 검사 시설에 대한 접근 부족이 조기 진단을 방해 : 검사 시설의 이용 가능성이 제한되어 있기 때문에 특히 충분한 서비스를 받지 않은 지역에서는 HCV 감염의 조기 진단이 방해될 가능성이 있습니다. 그 결과, 치료가 지연되어 합병증의 리스크가 높아질 가능성이 있습니다.
- 검사와 치료에 대한 접근을 방해하는 비용의 벽 : HCV의 검사와 치료에 드는 비용은 많은 사람들, 특히 저소득자층에 있어서 큰 장벽이 될 수 있습니다. 그 때문에 치료에의 액세스가 제한되어 조기 진단·치료가 방해될 가능성이 있습니다.
- 시장 확대를 막는 복잡한 규제 상황 : HCV 검사·치료에 관한 규제 상황의 파악은 특히 복수의 지역에서 사업을 전개하는 헬스 케어 프로바이더나 제조업자에게 있어서 복잡한 것이 됩니다.
주요 동향
- C형 간염 박멸 활동에 대한 주목이 높아짐 : C형 간염 박멸을 위한 세계의 대처가 검사 이니셔티브의 확대를 뒷받침하고 있습니다.
- 1차 케어에서 HCV 검사의 통합 확대 : 1차 케어에서 C형 간염 검사의 통합은 급속히 진행되고 있습니다.
- 정부의 이니셔티브와 자금 조달 추진 : 정부의 이니셔티브와 자금 제공 증가가 C형 간염 검사 시장을 전진시키고 있습니다. 미국 보건복지부는 2024 회계연도에 바이러스성 간염 예방 및 치료를 위해 3억 9천만 달러를 배정했으며, 이는 2023년에 비해 15% 증가한 금액입니다.
- 멀티플렉스 검사 플랫폼의 채용 증가 : 여러 간염 바이러스를 동시에 검출하기 위한 멀티플렉스 검사 플랫폼의 채용이 증가하고 있습니다.
목차
제1장 세계의 C형 간염 검사 시장 도입
제2장 주요 요약
제3장 VERIFIED MARKET RESEARCH의 조사 방법
- 데이터 마이닝
- 밸리데이션
- 1차 자료
- 데이터 소스 일람
제4장 세계의 C형 간염 검사 시장 전망
- 개요
- 시장 역학
- Porter's Five Forces 모델
- 밸류체인 분석
제5장 세계의 C형 간염 검사 시장 : 검사 키트별
- 개요
- C형 간염 항체 검사
- C형 간염 RNA 정량 검사
- C형 간염 RNA 정성 검사
- C형 간염 RIBA
- C형 간염 유전자형
- 바이러스 부하
제6장 세계의 C형 간염 검사 시장 : 최종 사용자별
제7장 세계의 C형 간염 검사 시장 : 기술별
- 개요
- 면역 측정법
- 중합효소 연쇄반응(PCR)
- 기타
제8장 세계의 C형 간염 검사 시장 : 지역별
제9장 세계의 C형 간염 검사 시장 경쟁 구도
제10장 기업 프로파일
- Siemens Healthineers
- Abbott Laboratories
- Roche Diagnostics
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- Streck
- Illumina Inc.
- Merck KGaA
- Qiagen
제11장 주요 개발
- 제품 출시/개발
- 합병과 인수
- 사업 확대
- 파트너십과 제휴
제12장 부록
KTH
Hepatitis C Testing Market Size And Forecast
Hepatitis C Testing Market size was valued at USD 1.48 Billion in 2024 and is projected to reach USD 2.51 Billion by 2032, growing at a CAGR of 7.50% from 2026 to 2032.
- Hepatitis C testing is a critical component of managing hepatitis C virus (HCV) infection. HCV is a blood-borne virus that can lead to severe liver damage if left untreated.
- HCV infection is highly treatable with antiviral medications. Effective treatment can lead to a cure, preventing the progression of liver disease.
- Early diagnosis and treatment are essential to prevent complications such as liver cirrhosis and liver cancer.
- According to the Centers for Disease Control and Prevention (CDC), nearly one in three people with hepatitis C are unaware of their infection status.
- CDC recommends universal hepatitis C screening for all adults 18 and older and all pregnant people during each pregnancy.
- CDC recommends testing people in certain high-risk groups more frequently.
Global Hepatitis C Testing Market Dynamics
The key market dynamics that are shaping the global hepatitis C testing market include:
Key Market Drivers
- Rising Prevalence of Hepatitis C: The increasing prevalence of Hepatitis C virus (HCV) infection is propelling the demand for testing. According to the World Health Organization, an estimated 58 million people were living with chronic HCV infection in 2023. This high prevalence underscores the urgent need for widespread testing and early diagnosis.
- Growing Awareness and Screening Programs: Expanding awareness campaigns and screening programs are driving growth in the Hepatitis C testing market. The U.S. Centers for Disease Control and Prevention reported a 32% increase in HCV testing rates from 2020 to 2023. These initiatives are crucial for identifying undiagnosed cases and preventing further transmission.
- Dominating Trend of Point-of-Care Testing: The shift towards rapid, point-of-care testing is dominating the Hepatitis C testing landscape. The U.S. Food and Drug Administration approved three new HCV point-of-care tests in 2023, demonstrating the growing importance of this approach. These tests enable faster diagnosis and treatment initiation.
- Propelling Advancements in Diagnostic Technologies: Technological advancements are propelling innovations in Hepatitis C testing methods. The global molecular diagnostics market, which includes HCV testing, is projected to reach $31.8 billion by 2026, according to the National Institutes of Health. These innovations are improving test accuracy and efficiency.
Key Challenges:
- Limited Awareness and Stigma Hindering Testing Rates: Many individuals at risk for HCV infection may not be aware of the symptoms or the importance of testing. Also, the stigma associated with HCV infection can deter individuals from seeking testing and treatment.
- Lack of Access to Testing Facilities Hampering Early Diagnosis: Limited availability of testing facilities, particularly in underserved areas, can hinder early diagnosis of HCV infection. This can lead to delayed treatment and increased risk of complications.
- Cost Barriers Obstructing Access to Testing and Treatment: The cost of HCV testing and treatment can be a significant barrier for many individuals, particularly in low-income communities. This can limit access to care and prevent early diagnosis and treatment.
- Complex Regulatory Landscape Challenging Market Expansion: Navigating the regulatory landscape for HCV testing and treatment can be complex, especially for healthcare providers and manufacturers operating in multiple jurisdictions. Compliance with regulatory requirements can increase costs and hinder market expansion.
Key Trends
- Rising Focus on Hepatitis C Elimination Efforts: Global efforts to eliminate Hepatitis C are driving increased testing initiatives. The World Health Organization reported that 21 countries were on track to achieve HCV elimination by 2030, as of 2023. These elimination programs are boosting demand for large-scale testing.
- Growing Integration of HCV Testing in Primary Care: The integration of Hepatitis C testing into primary care settings is growing rapidly. The European Centre for Disease Prevention and Control reported a 45% increase in HCV testing at primary care facilities from 2021 to 2023. This trend is improving access to testing and early diagnosis.
- Propelling Government Initiatives and Funding: Government initiatives and increased funding are propelling the Hepatitis C testing market forward. The U.S. Department of Health and Human Services allocated $390 million for viral hepatitis prevention and treatment in fiscal year 2024, a 15% increase from 2023. These investments are crucial for expanding testing programs.
- Rising Adoption of Multiplex Testing Platforms: The adoption of multiplex testing platforms for simultaneous detection of multiple hepatitis viruses is rising. The global multiplex diagnostics market, including hepatitis testing, was valued at $3.9 billion in 2023, according to the National Center for Biotechnology Information. This approach offers cost-effective and efficient testing solutions.
Global Hepatitis C Testing Market Regional Analysis
Here is a more detailed regional analysis of the global hepatitis C testing market:
North America
- North America dominates the global hepatitis C testing market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem.
- According to the National Institutes of Health (NIH), the U.S. invested $45.1 billion in biomedical research in fiscal year 2023, fueling innovation in the sector.
- This substantial funding has led to significant advancements in areas such as gene therapy and personalized medicine.
- For instance, in February 15, 2024, Moderna announced the expansion of its mRNA pipeline, including 15 new programs in rare diseases and oncology, further solidifying North America's leadership in hepatitis C testing.
- The region's market dominance is also driven by a high prevalence of chronic diseases and a supportive regulatory environment.
- The Centers for Disease Control and Prevention (CDC) reported that 6 in 10 adults in the U.S. have a chronic disease as of 2023, creating a strong demand for innovative biotechnology solutions.
- This demand is met by cutting-edge research and development efforts from industry leaders.
- For instance, on September 8, 2023, Pfizer received FDA approval for its gene therapy treatment for hemophilia B, marking a significant milestone in hepatitis C testing applications and reinforcing North America's position at the forefront of the global market.
Asia Pacific
- Asia Pacific is poised to emerge as the fastest-growing region in the global hepatitis C testing market during the forecast period, driven by the high prevalence, coupled with improving healthcare infrastructure and rising awareness, thus driving the market growth.
- According to the World Health Organization's Western Pacific Region office, an estimated 39 million people were living with chronic hepatitis C in the region as of 2023, highlighting the urgent need for enhanced testing efforts.
- On March 8, 2024, Abbott Laboratories announced the launch of its new rapid HCV test in India, aiming to increase access to quick and accurate diagnosis in resource-limited settings.
- The region's growth is further fueled by government initiatives and increasing healthcare expenditure. China's National Health Commission reported a 40% increase in hepatitis C screening rates from 2021 to 2023, demonstrating a strong commitment to disease control.
- also, the emerging economies are adopting advanced testing technologies to improve diagnostic accuracy and efficiency.
- On November 15, 2023, Roche Diagnostics partnered with the Malaysian Ministry of Health to provide 1 million HCV tests as part of a nationwide elimination program, showcasing the collaborative efforts between industry leaders and governments to combat hepatitis C in the Asia Pacific region.
Global Hepatitis C Testing Market: Segmentation Analysis
The Global Hepatitis C Testing Market is segmented based on Test Kits, Technique, End-User, and Geography.
Hepatitis C Testing Market, By Test Kits
- Hepatitis C Antibody Test
- Hepatitis C RNA Quantitative Test
- Hepatitis C RNA Qualitative Test
- Hepatitis C RIBA
- Hepatitis C Genotype
- Viral Load
Based on Test Kits, the Global Hepatitis C Testing Market is bifurcated into Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test, Hepatitis C RNA Qualitative Test, Hepatitis C RIBA, Hepatitis C Genotype, Viral Load. The hepatitis C RNA quantitative test segment is currently dominating the global hepatitis C testing market, driven by its ability to accurately measure the viral load of HCV infection. However, the hepatitis C genotype test segment is experiencing rapid growth, as understanding the HCV genotype is essential for selecting the most effective treatment regimen.
Hepatitis C Testing Market, By Technique
- Immunoassays
- Polymerase Chain Reaction (PCR)
- Others
Based on Technique, the Global Hepatitis C Testing Market is bifurcated into Immunoassays, Polymerase Chain Reaction (PCR), Others. The immunoassay segment is currently dominating the global hepatitis C testing market, owing to its established reputation for simplicity, affordability, and high sensitivity in detecting hepatitis C antibodies. However, polymerase chain reaction (PCR) segment is experiencing rapid growth, driven by its superior accuracy and ability to directly detect the hepatitis C virus, making it a valuable tool for early diagnosis and treatment monitoring.
Hepatitis C Testing Market, By End-User
- Hospitals
- Clinics
- Diagnostic Laboratories
- Others
Based on End-User, the Global Hepatitis C Testing Market is bifurcated into Hospital and Clinics, Diagnostic Laboratories, Others. The hospitals segment is currently dominating the global hepatitis C testing market, driven by the high volume of patients seeking testing and treatment in these facilities. However, the diagnostic laboratories segment is experiencing rapid growth, as healthcare providers increasingly rely on specialized laboratories for accurate and efficient testing services.
Hepatitis C Testing Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the world
Based on Geography, the Global Hepatitis C Testing Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominates the global hepatitis C testing market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem. However, Asia Pacific is poised to emerge as the fastest-growing region in the global hepatitis C testing market during the forecast period, driven by the high prevalence, coupled with improving healthcare infrastructure and rising awareness thus driving the market growth.
Key Players
The "Global Hepatitis C Testing Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott (U.S.), Bio-Rad Laboratories Inc., QIAGEN, Bayer AG, OraSure Technologies, Inc., Sysmex Corporation, Meridian Bioscience, Biogate Laboratories Ltd.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Global Hepatitis C Testing Market Key Developments
- In February 2023, the Pune-based company Mylab Discovery Solutions declared that it would be launching three new rapid tests to identify STIs in a timely manner. STIs are a serious problem since, according to WHO estimates, there will be one million STI cases worldwide each day.
- In September 2022, An IVD company called J Mitra unveiled the HCV Gen 4 Ag & Ab Microlisa, a fourth-generation Elisa-based HCV test. The purpose of the kit is to screen blood donors in order to identify and eliminate blood units that are contaminated. Hepatitis C can also be clinically diagnosed with this kit.
TABLE OF CONTENTS
1 INTRODUCTION OF GLOBAL HEPATITIS C TESTING MARKET
- 1.1 Introduction of the Market
- 1.2 Scope of Report
- 1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
- 3.1 Data Mining
- 3.2 Validation
- 3.3 Primary Interviews
- 3.4 List of Data Sources
4 GLOBAL HEPATITIS C TESTING MARKET OUTLOOK
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
5 GLOBAL HEPATITIS C TESTING MARKET, BY TEST KITS
- 5.1 Overview
- 5.2 Hepatitis C Antibody Test
- 5.3 Hepatitis C RNA Quantitative Test
- 5.4 Hepatitis C RNA Qualitative Test
- 5.5 Hepatitis C RIBA
- 5.6 Hepatitis C Genotype
- 5.7 Viral Load
6 GLOBAL HEPATITIS C TESTING MARKET, BY END-USERS
- 6.1 Overview
- 6.2 Hospitals
- 6.3 Clinics
- 6.4 Diagnostic Laboratories
- 6.5 Others
7 GLOBAL HEPATITIS C TESTING MARKET, BY TECHNOLOGY
- 7.1 Overview
- 7.2 Immunoassays
- 7.3 Polymerase Chain Reaction (PCR)
- 7.4 Others
8 GLOBAL HEPATITIS C TESTING MARKET, BY GEOGRAPHY
- 8.1 Overview
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
- 8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa
9 GLOBAL HEPATITIS C TESTING MARKET COMPETITIVE LANDSCAPE
- 9.1 Overview
- 9.2 Company Market Ranking
- 9.3 Key Development Strategies
10 COMPANY PROFILES
- 10.1 Siemens Healthineers
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
- 10.2 Abbott Laboratories
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
- 10.3 Roche Diagnostics
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
- 10.4 Bio-Rad Laboratories
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
- 10.5 Thermo Fisher Scientific
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
- 10.6 Streck
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
- 10.7 Illumina Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
- 10.8 Merck KGaA
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
- 10.9 Qiagen
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
11 KEY DEVELOPMENTS
- 11.1 Product Launches/Developments
- 11.2 Mergers and Acquisitions
- 11.3 Business Expansions
- 11.4 Partnerships and Collaborations
12 Appendix
